Genocea Biosciences Inc (GNCAQ)
Genocea Biosciences, Inc. was a biotechnology company focused on developing cancer immunotherapies. The company’s research platform, ATLAS, was designed to analyze CD4+ and CD8+ T cell immune responses against tumor antigens identified through next-generation sequencing of a patient’s tumor. Its pipeline included GEN-011, an adoptive T cell therapy being studied in Phase 1/2a trials for solid tumors, and GEN-009, a neoantigen vaccine candidate also in Phase 1/2a testing. Founded in 2006 and based in Cambridge, Massachusetts, Genocea filed for Chapter 11 reorganization in July 2022, and the case was later approved as a Chapter 11 liquidation in May 2023. The security is common stock listed on OTC Markets.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap |
|---|---|---|---|---|---|---|---|
|
OTC-GNCA.Q
|
Not available
|
Not available
|
Not available
|
Weak
|
0.0%
|
October 29, 2026
|
0.058 K
|
